Trevi Therapeutics Inc. (TRVI)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform
Trevi Therapeutics leverages Haduvio's dual mechanism to target IPF-related chronic cough, with expansion plans into non-IPF ILD and refractory chronic cough. Haduvio's positive Phase II data in both IPF and RCC, ongoing pivotal trials, and robust liquidity underpin TRVI's transition to a specialty pharma platform. TRVI's specialty-first strategy targets concentrated pulmonology networks, enabling efficient market entry and future expansion without large-scale commercial buildout.
Trevi Therapeutics Q2 Earnings Call Highlights
Trevi Therapeutics NASDAQ: TRVI said it began two clinical trials during the second quarter and plans to launch a third study in the third quarter as it advances nalbuphine ER, also known as Haduvio, for multiple chronic-cough indications.
Trevi Therapeutics, Inc. (TRVI) Q2 2026 Earnings Call Transcript
Trevi Therapeutics, Inc. (TRVI) Q2 2026 Earnings Call Transcript
Trevi Therapeutics, Inc. (TRVI) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Trevi Therapeutics, Inc. (TRVI) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030
Trevi Therapeutics NASDAQ: TRVI outlined plans to advance Haduvio, its extended-release formulation of nalbuphine, across multiple chronic cough indications, with management emphasizing upcoming clinical trial starts, a specialty commercial strategy and an extended cash runway following a recent financing.
Trevi Therapeutics, Inc. (TRVI) Q1 2026 Earnings Call Transcript
Trevi Therapeutics, Inc. (TRVI) Q1 2026 Earnings Call Transcript
Trevi Therapeutics, Inc. (TRVI) Q4 2025 Earnings Call Transcript
Trevi Therapeutics, Inc. (TRVI) Q4 2025 Earnings Call Transcript
Does Trevi Therapeutics (TRVI) Have the Potential to Rally 102.07% as Wall Street Analysts Expect?
The mean of analysts' price targets for Trevi Therapeutics (TRVI) points to a 102.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Trevi Therapeutics: "Buy" Rating For Haduvio Treating Chronic Cough In IPF And Beyond
Trevi Therapeutics (TRVI) is initiated with a "Buy" rating, driven by its lead asset Haduvio's advancement toward phase 3 testing for chronic cough in IPF. Company's Haduvio demonstrated statistically significant efficacy in phase 2b CORAL study [IPF] and phase 2a RIVER [RCC], with a differentiated dual central/peripheral mechanism of action. The company is well-capitalized, with $194.9M in cash and a projected runway into 2028, supporting upcoming pivotal trials.
Trevi Therapeutics, Inc. (TRVI) Q3 2025 Earnings Call Transcript
Trevi Therapeutics, Inc. ( TRVI ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Jennifer Good - Co-Founder, CEO, President, Interim Principal Financial Officer & Director James Cassella - Chief Development Officer Farrell Simon - Chief Commercial Officer Conference Call Participants Ryan Deschner - Raymond James & Associates, Inc., Research Division Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Judah Frommer - Morgan Stanley, Research Division Serge Belanger - Needham & Company, LLC, Research Division Roanna Clarissa Ruiz - Leerink Partners LLC, Research Division William Wood - B. Riley Securities, Inc., Research Division Kaveri Pohlman - Clear Street LLC Presentation Operator Good afternoon, and welcome to the Trevi Therapeutics Third Quarter 2025 Earnings Conference Call.
Trevi Therapeutics, Inc. (TRVI) Q2 2025 Earnings Call Transcript
Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants g - Corporate Participant e - Corporate Participant Farrell Simon - Chief Commercial Officer James V. Cassella - Chief Development Officer Jennifer L.
Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know
The mean of analysts' price targets for Trevi Therapeutics (TRVI) points to a 231.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
